Francois Eric 4

What Happened
Francois Eric, a director of CERO THERAPEUTICS HOLDINGS, INC. (CERO), received a derivative award on 2026-03-04 covering 1,823,278 shares. The award shows $0.00 paid at grant (i.e., no cash outlay reported). This was an award/grant (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-04-21 (filed about 48 days after the transaction — a late filing).
• Transaction type: A = Award/Grant/Acquisition of derivative securities (1,823,278 shares). Reported price: $0.00.
• Shares owned after transaction: not specified in the provided extract.
• Footnote: the shares underlying this option vest in full on the earlier of (i) August 13, 2026 or (ii) achievement of a specified clinical milestone in 2026, in each case contingent on the reporting person's continuous service.
• No indication in the filing that any shares were immediately sold or that a 10b5-1 plan or tax-withholding event applied.

Context
This was an award of derivative securities (an option-like award or RSU-style grant), meaning the insider did not buy shares on the open market. Vesting is conditional — either time-based (Aug 13, 2026) or milestone-based (a clinical milestone in 2026). Such grants are routine compensation/retention tools for executives and directors; they do not by themselves indicate an immediate purchase or sale of stock.